PCSK-9 inhibition in patients with recalcitrant hypercholesterolemia has reaped reductions in LDL-C of up to 85% after the first week of therapy.
Robert Giugliano, MD
Advertisement
Articles by Robert Giugliano, MD
Advertisement
Latest Updated Articles
- Lipid-lowering Injectable Antibodies: The Next Big Thing?
Published: November 29th 2012 | Updated:
Advertisement
Advertisement
Trending on Patient Care Online
1
Lilly's Novel Oral GLP-1 Orforglipron Shows Superior Efficacy in 2 Phase 3 Trials
2
FDA OKs Subcutaneous Guselkumab Regimen for Ulcerative Colitis: Daily Dose
3
"Shared Decision-Making" for COVID-19 Vaccination Signals "Optional" to Too Many, Says Kelly Moore, MD, MPH
4
FDA Approves Updated Indication Statement for Upadacitinib in Inflammatory Bowel Disease Treatment
5
